You are here: Home » Companies » News
Business Standard

Govt lifts ban on painkiller Analgin

The product was available under various popular brands such as Novalgin and Baralgan, which are now likely to gain from the lifting of the ban

BS Reporter  |  New Delhi 

The government has lifted the ban on painkiller and anti-pyretic drug Analgin and all formulations containing the drug, allowing pharmaceutical such as Sanofi and Alkem to re-launch their popular brands of the medicine in the market. However, selling the product will have to carry a warning on their package and promotional literature of the drug specifying its usage, a gazette notification published by the Ministry of Health and Family Welfare said.

The product was available under various popular brands such as Novalgin and Baralgan, which are now likely to gain from the lifting of the ban.

"On the basis of the recommendations of the Drugs Technical Advisory Board, the Central government hereby revokes the notification G.S.R 378(E) dated 18th June, 2013 subject to the condition that manufacturers shall mention the following on their package insert and promotional literature of the drug...," the notification said specifying the content as : "The drug is indicated for severe pain or pain due to tumor and also for bringing down temperature in refractory cases when other antipyretics fail to do so."

Analgin is banned in most parts of the world including in the US, Australia, Japan, Canada, Sweden and France. It was also barred in a few developing countries such as Nigeria and Nepal.

India had decided to suspend sale and distribution of the drug in June last year after it received representation from various forums, mainly criticism from Parliamentary Standing Committee, suggesting side-effects from the medicine and the fact that it is restricted in most parts of the world.

However, soon after the suspension the matter was taken up by the Drug Technical Advisory Board (DTAB) during November last year. The advisory board said that the duration of Analgin treatment was only a few days and, therefore, the use of the drug might be continued according to the approved indication.

According to the notification, the ban on Analgin has been revoked based on DTAB?s recommendations.

Though the total market for Analgin is estimated to be smaller at around Rs 100 crore annually, market analyst say few established brands hold majority of this market while there are many other small and unorganized players also selling the drug, sales data for which may not be generated or available. There are also alternatives of the drug available in the market.

Analgin is not the only drug coming back to market soon after facing a suspension order. Along with Analgin, the government had also suspended sale of an anti-diabetic drug pioglitazone in June last year. However, within less than two months, it revoked the ban on pioglitazone, in the absence of substantial scientific evidence showing the adverse effect of the drug on Indian patients.

Experts point out that the current move of the government to revoke the ban on Analgin could be motivated as drug, which does not appear in the National List of Essential Medicines (NLEM), is not under price control.

?Analgin is very cheap to manufacture and many Indian may, therefore, like to sell the product,? says Amit Sengupta, a medical practitioner and also the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement.

According to Sengupta, the problem with the regulatory system in India is that there is no framework to generate data related to adverse drug reactions.

ALSO READ: Pharma firms might resume sales of analgin-based drugs

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, March 19 2014. 18:10 IST